Virginia Robles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Virginia Robles has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Herrera-Deguise
Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Hospital Universitari Vall d’Hebron , Barcelona
4 shared publications Natalia Borruel
Crohn's and Colitis Attention Unit, Digestive System Service, Universitary Hospital Vall d'Hebron, Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
4 shared publications- Ester Navarro
Ester Navarro-Correal, MSc, MSN, RN, is Nurse, PhD Student Programme on Health, Nurse and Physiotherapy Department at University of Lleida, Lleida, Spain; Crohn-Colitis Care Unit, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Multidisciplinary Nursing Research Group of Vall d'Hebron Research Institute, Barcelona, Spain
3 shared publications - Francesc Casellas
Servicio de Digestivo, Hospital Universitari Vall d'Hebron, España
3 shared publications - David Busquets
Hospital Universitari de Girona Doctor Josep Trueta, 17007 Girona, Spain
2 shared publications - Elena Céspedes-Martínez
Unitat d’Atenció Crohn-Colitis (UACC), Servicio de Aparato Digestivo, Hospital Universitario Vall d’Hebron, 08035 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 18
Higher ustekinumab concentrations in induction are associated with better endoscopic outcomes in inflammatory bowel disease
Background: Evidence suggests a relationship between ustekinumab (UST) concentrations and therapeutic outcomes in inflammatory bowel disease. Objectives: This study aimed to evaluate the association between UST concentrations during the induction phase and treatment outcomes at week 24 in patients with Crohn’s disease (CD) and ulcerative colitis (UC). The primary outcome was endoscopic remission at week 24, defined as a simple endoscopic score (SES-CD) ⩽2 for CD and a Mayo endoscopic score = 0 for UC. Secondary outcomes included endoscopic response, clinical remission, and treatment persistence. Design: This was a prospective observational study assessing clinical and endoscopic outcomes in CD and UC patients starting UST therapy. Methods: Consecutive patients with CD and UC were included at the initiation of UST treatment. Trough UST concentrations were measured at weeks 8, 16, and 24 after the first intravenous dose, and the main outcomes were assessed at week 24. Endoscopic and clinical parameters were used to evaluate treatment efficacy and persistence. Results: Seventy patients (45 with CD) were enrolled. Those achieving endoscopic remission and response at week 24 had higher UST levels at week 8 (4.5 vs 2.6 μg/mL, p = 0.0028; 4.1 vs 2.4 μg/mL, p = 0.0024, respectively). Patients with UST concentrations in the fourth quartile (Q4) at week 8 (>4.5 μg/mL) had higher rates of endoscopic remission (66.7% (Q4) vs 20% (Q1); 33.3% (Q2); 28.6% (Q3); p = 0.012). A UST concentration threshold of 4.5 μg/mL at week 8 was the best predictor of endoscopic remission (AUC = 0.7, sensitivity 54.5%, specificity 83.8%), while 3.5 μg/mL predicted endoscopic response (AUC = 0.732, sensitivity 53.8%, specificity 87%). Longer disease duration correlated with a higher risk of UST discontinuation (odds ratio, 1.034, 95% confidence interval, 1.002–1.068, p = 0.035). Higher UST concentrations in Q4 did not result in greater drug persistence ( p = 0.319). Conclusion: UST concentrations at week 8 were positively associated with endoscopic outcomes at week 24, with a threshold of 4.5 μg/mL reliably predicting endoscopic remission. Further randomized clinical trials are warranted to explore whether optimizing UST treatment based on post-induction concentrations can enhance therapeutic outcomes.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 18
Open AccessHigher ustekinumab concentrations in induction are associated with better endoscopic outcomes in inflammatory bowel disease
Background: Evidence suggests a relationship between ustekinumab (UST) concentrations and therapeutic outcomes in inflammatory bowel disease. Objectives: This study aimed to evaluate the association between UST concentrations during the induction phase and treatment outcomes at week 24 in patients with Crohn’s disease (CD) and ulcerative colitis (UC). The primary outcome was endoscopic remission at week 24, defined as a simple endoscopic score (SES-CD) ⩽2 for CD and a Mayo endoscopic score = 0 for UC. Secondary outcomes included endoscopic response, clinical remission, and treatment persistence. Design: This was a prospective observational study assessing clinical and endoscopic outcomes in CD and UC patients starting UST therapy. Methods: Consecutive patients with CD and UC were included at the initiation of UST treatment. Trough UST concentrations were measured at weeks 8, 16, and 24 after the first intravenous dose, and the main outcomes were assessed at week 24. Endoscopic and clinical parameters were used to evaluate treatment efficacy and persistence. Results: Seventy patients (45 with CD) were enrolled. Those achieving endoscopic remission and response at week 24 had higher UST levels at week 8 (4.5 vs 2.6 μg/mL, p = 0.0028; 4.1 vs 2.4 μg/mL, p = 0.0024, respectively). Patients with UST concentrations in the fourth quartile (Q4) at week 8 (>4.5 μg/mL) had higher rates of endoscopic remission (66.7% (Q4) vs 20% (Q1); 33.3% (Q2); 28.6% (Q3); p = 0.012). A UST concentration threshold of 4.5 μg/mL at week 8 was the best predictor of endoscopic remission (AUC = 0.7, sensitivity 54.5%, specificity 83.8%), while 3.5 μg/mL predicted endoscopic response (AUC = 0.732, sensitivity 53.8%, specificity 87%). Longer disease duration correlated with a higher risk of UST discontinuation (odds ratio, 1.034, 95% confidence interval, 1.002–1.068, p = 0.035). Higher UST concentrations in Q4 did not result in greater drug persistence ( p = 0.319). Conclusion: UST concentrations at week 8 were positively associated with endoscopic outcomes at week 24, with a threshold of 4.5 μg/mL reliably predicting endoscopic remission. Further randomized clinical trials are warranted to explore whether optimizing UST treatment based on post-induction concentrations can enhance therapeutic outcomes.
- Open Access
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients
Background: Studies investigating the long-term cellular immune response to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD) remain limited, particularly among those receiving immunosuppressive therapy. Methods: We prospectively evaluated humoral and cellular immune responses at short-term (4–6 weeks) and long-term (6–12 months) time points following SARS-CoV-2 mRNA vaccination in patients with IBD receiving anti-TNF agents, thiopurines, or combination therapy. We defined the short-term response as the measurement taken 4–6 weeks after the second vaccine dose and the long-term response as the measurement taken between 6 and 12 months after the first determination. A cohort of healthy controls was included for short-term comparative analysis. Results: At long-term follow-up, quantitative humoral responses were reduced in patients receiving anti-TNF monotherapy. In contrast, a reduced quantitative cellular response was found in the thiopurine (median 0.7 UI/mL, p < 0.05) and anti-TNF combo groups (median 0.4 UI/mL, p < 0.01) compared to anti-TNF monotherapy (median 2.2 UI/mL). Conclusions: There was a robust long-term humoral and cellular response to vaccination, but a diminished quantitative cellular response in patients treated with thiopurines or combo therapy compared to anti-TNF monotherapy.
Open AccessImpaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients
Background: Studies investigating the long-term cellular immune response to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD) remain limited, particularly among those receiving immunosuppressive therapy. Methods: We prospectively evaluated humoral and cellular immune responses at short-term (4–6 weeks) and long-term (6–12 months) time points following SARS-CoV-2 mRNA vaccination in patients with IBD receiving anti-TNF agents, thiopurines, or combination therapy. We defined the short-term response as the measurement taken 4–6 weeks after the second vaccine dose and the long-term response as the measurement taken between 6 and 12 months after the first determination. A cohort of healthy controls was included for short-term comparative analysis. Results: At long-term follow-up, quantitative humoral responses were reduced in patients receiving anti-TNF monotherapy. In contrast, a reduced quantitative cellular response was found in the thiopurine (median 0.7 UI/mL, p < 0.05) and anti-TNF combo groups (median 0.4 UI/mL, p < 0.01) compared to anti-TNF monotherapy (median 2.2 UI/mL). Conclusions: There was a robust long-term humoral and cellular response to vaccination, but a diminished quantitative cellular response in patients treated with thiopurines or combo therapy compared to anti-TNF monotherapy.
- 26 September 2024
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 48 (6) , 502258
Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD
- 26 September 2024
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 48 (6) , 502258
Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD
- 1 September 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (9) , 973-977
Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment
- 1 September 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (9) , 973-977
Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment
- Open Access
- 1 June 2016
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 22 (6) , 1450-1455
Iron Deficiency in the Absence of Anemia Impairs the Perception of Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
Background. Anemia is a common complication of inflammatory bowel disease (IBD) and contributes to the deterioration of health-related quality of life (HRQOL).
- 1 June 2016
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 22 (6) , 1450-1455
Open AccessIron Deficiency in the Absence of Anemia Impairs the Perception of Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
Background. Anemia is a common complication of inflammatory bowel disease (IBD) and contributes to the deterioration of health-related quality of life (HRQOL).
- Open Access
- 24 November 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 43 (3) , 400-426
Current concepts on microscopic colitis: evidence‐based statements and recommendations of the Spanish Microscopic Colitis Group
Summary: Background: Microscopic colitis (MC) is an underdiagnosed inflammatory bowel disease.Aim: To develop an evidence‐based clinical practice guide on MC current concepts.Methods: Literature search was done on the Cochrane Library, EMBASE and MEDLINE electronic databases, which were consulted covering the period up until March 2015. Work groups were selected for each of the reviewed topics, with the purpose of drafting the initial statements and recommendations. They subsequently underwent a voting process based on the Delphi method. Each statement/recommendation was accompanied by the result of the vote the level of evidence, and discussion of the corresponding evidence. The grade of recommendation (GR) using the GRADE approach was established for diagnosis and treatment recommendations.Results: Some key statements and recommendations are: advancing age increases the risk of developing MC, mainly in females. The symptoms of MC and IBS‐D may be similar. If MC is suspected, colonoscopy taking biopsies is mandatory. Treatment with oral budesonide is recommended to induce clinical remission in patients with MC. Oral mesalazine is not recommended in patients with collagenous colitis for the induction of clinical remission. The use of anti‐TNF‐alpha drugs (infliximab, adalimumab) is recommended for the induction of remission in severe cases of MC that fail to respond to corticosteroids or immunomodulators, as an alternative to colectomy.Conclusions: This is the first consensus paper on MC based on GRADE methodology. This initiative may help physicians involved in care of these patients in taking decisions based on evidence.
- 24 November 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 43 (3) , 400-426
Open AccessCurrent concepts on microscopic colitis: evidence‐based statements and recommendations of the Spanish Microscopic Colitis Group
Summary: Background: Microscopic colitis (MC) is an underdiagnosed inflammatory bowel disease.Aim: To develop an evidence‐based clinical practice guide on MC current concepts.Methods: Literature search was done on the Cochrane Library, EMBASE and MEDLINE electronic databases, which were consulted covering the period up until March 2015. Work groups were selected for each of the reviewed topics, with the purpose of drafting the initial statements and recommendations. They subsequently underwent a voting process based on the Delphi method. Each statement/recommendation was accompanied by the result of the vote the level of evidence, and discussion of the corresponding evidence. The grade of recommendation (GR) using the GRADE approach was established for diagnosis and treatment recommendations.Results: Some key statements and recommendations are: advancing age increases the risk of developing MC, mainly in females. The symptoms of MC and IBS‐D may be similar. If MC is suspected, colonoscopy taking biopsies is mandatory. Treatment with oral budesonide is recommended to induce clinical remission in patients with MC. Oral mesalazine is not recommended in patients with collagenous colitis for the induction of clinical remission. The use of anti‐TNF‐alpha drugs (infliximab, adalimumab) is recommended for the induction of remission in severe cases of MC that fail to respond to corticosteroids or immunomodulators, as an alternative to colectomy.Conclusions: This is the first consensus paper on MC based on GRADE methodology. This initiative may help physicians involved in care of these patients in taking decisions based on evidence.
- 24 January 2015
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 30 (2) , 286-291
Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents
Background and Aim: Crohn's disease (CD) impairs patients' health‐related quality of life (HRQoL), therefore a goal of treatment is to improve their health. Recently, a more ambitious therapeutic target has been proposed, to reestablish patients' HRQoL to normal standards. There is no information on long‐term prognostic value of restoring the health of patients with CD. Our aim was to determine if early restoration of HRQoL with antitumor necrosis factor (anti‐TNF) agents is associated with long‐term clinical remission.Methods: Retrospective longitudinal study in patients with active CD treated with anti‐TNF agents. Patients completed the Inflammatory Bowel Disease Questionnaire (IBDQ)‐36 at baseline and weeks 2, 6, 14, 28, and 52. Early restoration of health was defined as an IBDQ‐36 score > 209 at week14, and long‐term clinical remission as a Cohn's disease activity index (CDAI) score < 150 maintained through week 52.Results: Ninety‐four patients were included. Sixty‐three patients maintained long‐term remission, with 47 (75%) of them achieving early restoration of HRQoL. Of the 31 patients who did not maintain long‐term remission, only 4 (13%) restored their HRQoL early (P < 0.01). There was a strong negative correlation between the IBDQ‐36 at week14 and CDAI values at week 52 (rs = − 0.64, P < 0.01). Ninety‐two percent of patients with early restoration of HRQoL maintained long‐term remission versus 37% who did not restore their HRQoL (P < 0.01). To predict long‐term remission, the cutoff point of 209 of the early IBDQ‐36 had an area under the receiver operating characteristic (AUROC) curve of 0.87.Conclusion: Achieving early restoration of HRQoL with anti‐TNF agents is associated with sustained long‐term remission. This could be a therapeutic goal of treatment in clinical trials and daily practice.
- 24 January 2015
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 30 (2) , 286-291
Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents
Background and Aim: Crohn's disease (CD) impairs patients' health‐related quality of life (HRQoL), therefore a goal of treatment is to improve their health. Recently, a more ambitious therapeutic target has been proposed, to reestablish patients' HRQoL to normal standards. There is no information on long‐term prognostic value of restoring the health of patients with CD. Our aim was to determine if early restoration of HRQoL with antitumor necrosis factor (anti‐TNF) agents is associated with long‐term clinical remission.Methods: Retrospective longitudinal study in patients with active CD treated with anti‐TNF agents. Patients completed the Inflammatory Bowel Disease Questionnaire (IBDQ)‐36 at baseline and weeks 2, 6, 14, 28, and 52. Early restoration of health was defined as an IBDQ‐36 score > 209 at week14, and long‐term clinical remission as a Cohn's disease activity index (CDAI) score < 150 maintained through week 52.Results: Ninety‐four patients were included. Sixty‐three patients maintained long‐term remission, with 47 (75%) of them achieving early restoration of HRQoL. Of the 31 patients who did not maintain long‐term remission, only 4 (13%) restored their HRQoL early (P < 0.01). There was a strong negative correlation between the IBDQ‐36 at week14 and CDAI values at week 52 (rs = − 0.64, P < 0.01). Ninety‐two percent of patients with early restoration of HRQoL maintained long‐term remission versus 37% who did not restore their HRQoL (P < 0.01). To predict long‐term remission, the cutoff point of 209 of the early IBDQ‐36 had an area under the receiver operating characteristic (AUROC) curve of 0.87.Conclusion: Achieving early restoration of HRQoL with anti‐TNF agents is associated with sustained long‐term remission. This could be a therapeutic goal of treatment in clinical trials and daily practice.
- Open Access
- 1 March 2013
- Published by SciELO Espana/Repisalud in Revista Española de Enfermedades Digestivas
- Vol. 105 (3) , 144-153
Questionnaires for measuring fatigue and its impact on health perception in inflammatory bowel disease
Introduction: fatigue impacts perceived health, but its importance in inflammatory bowel disease is not known. Objectives: to define the applicability of the fatigue measurement questionnaires and analyze it in patients with Crohn's disease and ulcerative colitis. Material and methods: in a first phase, the psychometric properties of 3 fatigue measurement questionnaires were determined in 99 patients: Daily Fatigue Impact Scale, Fatigue Severity Scale, and Modified Fatigue Impact Scale. In a second phase, fatigue status and its relationship to disease and quality of life was determined in 127 patients and 69 healthy controls. Results: the first part of the study showed the applicability of the questionnaires listed in inflammatory bowel disease, the Daily Fatigue Impact Scale (DFIS) having the best correlation with the quality of life and clinical activity. In the second phase, significantly higher levels of fatigue were observed in active disease than in disease in remission and healthy controls (p < 0,05). The severity of fatigue was significantly correlated with quality of life (r = -0.66 and -0.72 between IBDQ-9 and DFIS and in Crohn's disease and ulcerative colitis, respectively) and with disease activity (r = 0.25 and Crohn's disease and ulcerative colitis, respectively, p < 0.05). Conclusions: in inflammatory bowel disease, fatigue measurement questionnaires have good properties and show that fatigue is an important manifestation of the disease, which has a significant impact on quality of life of patients.
- 1 March 2013
- Published by SciELO Espana/Repisalud in Revista Española de Enfermedades Digestivas
- Vol. 105 (3) , 144-153
Open AccessQuestionnaires for measuring fatigue and its impact on health perception in inflammatory bowel disease
Introduction: fatigue impacts perceived health, but its importance in inflammatory bowel disease is not known. Objectives: to define the applicability of the fatigue measurement questionnaires and analyze it in patients with Crohn's disease and ulcerative colitis. Material and methods: in a first phase, the psychometric properties of 3 fatigue measurement questionnaires were determined in 99 patients: Daily Fatigue Impact Scale, Fatigue Severity Scale, and Modified Fatigue Impact Scale. In a second phase, fatigue status and its relationship to disease and quality of life was determined in 127 patients and 69 healthy controls. Results: the first part of the study showed the applicability of the questionnaires listed in inflammatory bowel disease, the Daily Fatigue Impact Scale (DFIS) having the best correlation with the quality of life and clinical activity. In the second phase, significantly higher levels of fatigue were observed in active disease than in disease in remission and healthy controls (p < 0,05). The severity of fatigue was significantly correlated with quality of life (r = -0.66 and -0.72 between IBDQ-9 and DFIS and in Crohn's disease and ulcerative colitis, respectively) and with disease activity (r = 0.25 and Crohn's disease and ulcerative colitis, respectively, p < 0.05). Conclusions: in inflammatory bowel disease, fatigue measurement questionnaires have good properties and show that fatigue is an important manifestation of the disease, which has a significant impact on quality of life of patients.